University of Virginia Natural History Study
Part of paid clinical trials in Charlottesville, Virginia.
- Sponsor
- University of Virginia
- Study ID
- NCT04896138
- Status
- Enrolling By Invitation
Conditions
- Connective Tissue Diseases
- Hypersensitivity Pneumonitis
- Idiopathic Interstitial Pneumonias
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Sarcoidosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Interstitial Lung Disease — OTHERNot applicable - this is not an interventional trial
Study Details
Data and specimens will be collected longitudinally from patients seen in the UVA Interstitial Lung Disease (ILD) clinic in order to describe the phenotypic expression of various interstitial lung diseases. Samples will also be collected from a control group for comparison purposes. All data will be entered into a repository for future research purposes or screening for new studies that become available. This data will help identify trends and hopefully lead to a better understanding of the disease progression, treatment options, and outcomes.
Key Dates
- Start date
- Aug 28, 2018
- Status verified
- May 2024
- Primary completion
- Aug 31, 2035
- Completion
- Aug 31, 2035
Study Design
- Enrollment
- 2,500 participants (estimated)
Arms
- Arm: ILD CohortPatients with Interstitial Lung Disease seen at the UVA ILD or Pulmonary Clinic
- Arm: Control CohortControl group of patients and family members of those with an Interstitial Lung Disease
Primary Outcome Measure
Clinical Course of Disease [ Time Frame: Yearly from date of consent until subject is lost to follow-up or death occurs, whichever comes first, assessed up to 144 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Virginia Health System | Charlottesville | Virginia | 22908 | - |
Find similar trials in Charlottesville, VA
Related Studies
- Cardiac Sarcoidosis Randomized TrialPHASE3 · Recruiting · Ottawa Heart Institute Research Corporation · New Haven, Connecticut
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung DiseasePHASE3 · Enrolling By Invitation · United Therapeutics · Birmingham, Alabama
- Global Utilization And Registry Database for Improved preservAtion of doNor LUNGsEnrolling By Invitation · Paragonix Technologies · Phoenix, Arizona